Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
Martina Lehnert, Heinz Ludwig, Niklas Zojer
1st Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
Abstract: The development of radiolabeled antibodies against CD20 has facilitated targeted treatment of follicular lymphoma (FL). By using 90Y-ibritumomab tiuxetan (Zevalin®), a radionuclide (yttrium-90, linked by the chelator tiuxetan to the antibody ibritumomab) is brought into the vicinity of lymphoma cells. By the so-called cross-fire effect, this beta emitter has the capacity to destroy not only the lymphoma cells having bound the antibody, but also neighboring lymphoma cells. Currently this antibody is licensed in the European Union for use in relapsed or refractory FL. It is anticipated that this drug will also be approved for use as consolidation therapy after successful first-line treatment. Here we first will review the published literature supporting the use of 90Y-ibritumomab tiuxetan in the aforementioned indications and emerging data showing applicability of ibritumomab tiuxetan as sole first-line therapy for FL, as well as in the transplant setting. Possible strategies of incorporating ibritumomab tiuxetan into the treatment algorithm of FL are discussed.
Keywords: follicular lymphoma, 90Y-ibritumomab tiuxetan
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.